Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
Pfizer antiviral pill could be risky with other widely used medications
"Some of these potential interactions are not trivial, and some pairings have to be avoided altogether," Peter Anderson, a professor of pharmaceutical sciences at the University of Colorado told NBC News.
In a statement to The Hill, a Pfizer spokesperson said, "The potential for drug-drug interactions (DDI) for Paxlovid was examined in a series of in vitro studies, as well as clinical DDI studies [AKA adverse events (AEs) AKA adverse drug reactions (ADRs)]."
WHICH clinical studies of WHICH drugs and WHICH study criteria--latitudinal, longitudinal, medical history, "end-points," sample size, etc?
The spokesperson further elaborated on the antiviral pill and said that Paxlovid is comprised of the active  protease inhibitor Nirmatrelvir [total mg p.d.?], as well as a low-dose of 100 mg of Ritonavir [total mg p.d.?].  

"Its effect on drug metabolism may result in drug interactions, and some drugs may be contra-indicated. However, in light of the fact that Paxlovid has a short duration of treatment of five days [Rx "course" ≠ active ingredient half-life], combined with a low dose of Ritonavir of 100 milligrams, we believe that healthcare professionals [sic; s/b patients] should find most DDIs to be generally manageable ["tolerable"]," the statement reads.

supra ya think
immunomodulating industry; half-life, wash-out period
by Cat on Mon Dec 27th, 2021 at 04:46:49 PM EST
Thu May 7th, 2020
"commonly prescribed" corticosteroids, *mabs, *ides, *ates, and ACE, ACE2 inhibitors

scantily clad, authoritative DDI reference

by Cat on Mon Dec 27th, 2021 at 04:57:22 PM EST
[ Parent ]


Occasional Series